Positive Phase 1 results for LTG-001, Latigo’s potential best-in-class non-opioid Nav1.8 inhibitor, demonstrated it to be well tolerated with rapid absorption Dr. Singla brings world-class expertise in analgesics, pain management, and clinical development to accelerate Company’s pipeline…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.